9.97
-4.87%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Revenio Group Oyj
Its shares trade on Nasdaq Helsinki under the ticker REG1V.HE. It has been listed since 1 January 2003. In the fiscal year to 31 December 2025, it reported revenue of €109.7m and net income of €17.4m. At that date it held total assets of €150.6m and shareholders' equity of €114.7m.
Revenio Group Oyj is a globally operating health technology, which engages in the detection of glaucoma, osteoporosis, skin cancer, and asthma. The company is headquartered in Vantaa, Etela-Suomen. The company went IPO on 2003-01-01. The Company’s activities are divided into two business areas: Revenio Health Tech, which is responsible for the design, manufacture and sale of tonometers and bone density measurement devices; as well as Revenio Technology and Services, which provides contact center services for material handling systems. The company distributes products in a range of countries, including the United States, Canada, Australia, Japan and India. Furthermore, the Company is a parent of Done Medical Oy, Kauhajoen Sisalogistiikka Oy, Icare Finland Oy, Oscare Medical Oy and Midas Touch Oy, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 1 Jan 2003
- Employees
- 126
- Website
- reveniogroup.fi ↗
Leadership
Pay as last reported
- Mr. Arne NielsenIndependent Chairman of the Board€32,700
- Mr. Jouni ToijalaPresident, Chief Executive Officer, Member of the Management Board€132,284
- Mr. Robin PulkkinenChief Financial Officer, Member of the Management Team
- Mr. Ari IsomakiVice President - Operations, Member of the Management Board
- Mr. John FloydVice President - Sales, Member of the Management Board
- Mr. Erkki TalaVice President - Products, Brand and Marketing, Member of the Management Board
- Ms. Hanna VuornosVice President of People and Culture, Member of the Management Board
- Ms. Heli HuopaniemiVice President - Quality, Member of the Management Board
- Dr. Kate TaylorVice President - Strategy and Business Development, Member of the Management Board
- Mr. Marco RizzardoVice President - Research & Development, Member of the Management Board
- Ms. Heli LindforsIndependent Director
- Ms. Anat LoewensteinIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Revenio Group Oyj has several strengths that contribute to its success in the market. Firstly, the company holds a strong portfolio of innovative medical technology products, which enables it to cater to the needs of various healthcare sectors. This diverse product range gives Revenio Group a competitive edge over its rivals.
- Moreover, the company has established strong partnerships with leading healthcare providers and institutions worldwide. These partnerships not only help in expanding the company's market reach but also enhance its credibility among potential customers and investors.
Weaknesses
- Despite its strengths, there are a few weaknesses that Revenio Group Oyj needs to address. One major weakness is its dependency on a limited number of key suppliers for critical components. This dependence exposes the company to supply chain risks, which may impact its production capabilities and lead to potential delays or disruptions.
- Additionally, Revenio Group faces challenges in terms of brand recognition and market penetration in certain regions. The company needs to invest in targeted marketing strategies and expand its distribution channels to overcome these weaknesses and reach a wider customer base.
Opportunities
- Revenio Group Oyj operates in an industry that offers immense growth opportunities. One major opportunity lies in the increasing demand for advanced medical technology solutions worldwide. The company can capitalize on this demand by continuously innovating its product portfolio and introducing breakthrough technologies.
- Furthermore, the growing trend of remote healthcare and telemedicine presents a significant opportunity for Revenio Group. By leveraging its expertise in remote monitoring devices and software solutions, the company can tap into this emerging market and offer cost-effective solutions that enhance patient care.
Threats
- Along with opportunities, Revenio Group Oyj faces certain threats that could impact its growth potential. One major threat is intense competition from both established players and new entrants in the medical technology industry. To stay ahead, the company needs to continuously innovate, differentiate its products, and maintain high-quality standards.
- Additionally, regulatory and compliance requirements pose a threat to Revenio Group's operations. Adapting to changing regulations and ensuring strict compliance can be challenging and require dedicated resources and expertise.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.